Last reviewed · How we verify
Lasix ® Infusion
Lasix ® Infusion is a Small molecule drug developed by SQ Innovation, Inc.. It is currently in Phase 1 development. Also known as: Sanofi Aventis 20mg/2mL Lasix infusion.
Lasix Infusion is a medication used to treat conditions such as Chronic Kidney Diseases, Renal Transplantation, Heart Failure, and Fluid Overload. It works by inhibiting the sodium-(potassium)-chloride cotransporter 2, a mechanism that helps to reduce fluid overload.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Lasix ® Infusion |
|---|---|
| Also known as | Sanofi Aventis 20mg/2mL Lasix infusion |
| Sponsor | SQ Innovation, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Increase in creatinine > 0.3 from discharge to end-of-study visit blood test
- Potassium ≤ 3.0
Key clinical trials
- Study to Compare Bioavailability and Pharmacokinetics of a Novel Furosemide Regimen Administered Subcutaneously Versus the Same Dose (80 mg) Administered Intravenously in Healthy Volunteers (PHASE1)
- Early Discharge With Subcutaneous Furosemide Versus Standard Care in Acute Heart Failure (PHASE3)
- Remimazolam Infusion in Kidney Transplant Patients: A Multicenter Study (PHASE1)
- Furoscix in Heart Failure Patients With Diuretic Resistance (PHASE2)
- Use of a Novel SUBCUTaneous Preparation of Furosemide to Facilitate Early Supported Discharge of Patients With Heart Failure (PHASE2)
- Implementation of Fluid Strategies Using Real-time Bioelectrical Analyzer in Surgical Intensive Care Unit (SICU) (NA)
- Effects of Adding Hypertonic Saline Solutions and/or Etilefrine to Standard Diuretics Therapy in Hepatic Ascites (PHASE2)
- An Open Label Study to Evaluate the Impact of Duration of Subcutaneous Infusion of a Novel, pH Neutral Formulation of Furosemide (Furoscix®) on Safety and Local Skin Tolerability (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lasix ® Infusion CI brief — competitive landscape report
- Lasix ® Infusion updates RSS · CI watch RSS
- SQ Innovation, Inc. portfolio CI
Frequently asked questions about Lasix ® Infusion
What is Lasix ® Infusion?
Who makes Lasix ® Infusion?
Is Lasix ® Infusion also known as anything else?
What development phase is Lasix ® Infusion in?
What are the side effects of Lasix ® Infusion?
Related
- Manufacturer: SQ Innovation, Inc. — full pipeline
- Also known as: Sanofi Aventis 20mg/2mL Lasix infusion
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing